Changchun High-Tech announced that its subsidiary, Jinsai Pharmaceutical, has entered into an allergen-specific immunotherapy (AIT) collaboration with ALK-Abelló A/S of Denmark. The collaboration will see the two companies jointly develop and commercialize ALK's house dust mite (HDM) allergen-specific immunotherapy products in China, and the company will also acquire exclusive distribution rights for three ALK-developed products in mainland China. Under the agreement, Jinsai will pay an initial payment of €32.7 million. Based on the progress of regulatory approvals for the clinical trial of ACARIZAX (a sublingual tablet for the dust mite allergen) for adult, adolescent, and pediatric indications in China, Jinsai will pay regulatory milestone payments of €40 million. Based on the performance of these products in the Chinese market, Jinsai may also make sales milestone payments of €105 million.